Since the identified association of the poor prognosis and chemoresistance in AMLs with the PI3K/Akt/mTOR activation, we herein investigated the antiproliferative activity of FD268 against five hematological cancer cell lines: HL-60, MOLM-16, Mv-4-11, KG-1 and EOL-1. Here, MTOR is linked to hematopoietic and lymphoid cell neoplasm.